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Therapeutic effects of anti-
HMGB1 monoclonal antibody 
on pilocarpine-induced status 
epilepticus in mice
Li Fu1, Keyue Liu1, Hidenori Wake1, Kiyoshi Teshigawara1, Tadashi Yoshino2, Hideo 
Takahashi3, Shuji Mori4 & Masahiro Nishibori1
Inflammatory processes in brain tissue have been described in human epilepsy of various etiologies 
and in experimental models of seizures. High mobility group box-1 (HMGB1) is now recognized as 
representative of damage-associated molecular patterns (DAMPs). In the present study, we focused on 
whether anti-HMGB1 antibody treatment could relieve status epilepticus- triggered BBB breakdown 
and inflammation response in addition to the seizure behavior itself. Pilocarpine and methyl-
scopolamine were used to establish the acute seizure model. Anti-HMGB1 mAb showed inhibitory 
effects on leakage of the BBB, and on the HMGB1 translocation induced by pilocarpine. The expression 
of inflammation-related factors, such as MCP-1, CXCL-1, TLR-4, and IL-6 in hippocampus and cerebral 
cortex were down-regulated by anti-HMGB1 mAb associated with the number of activated astrocytes, 
microglial cells as well as the expression of IL-1β. Both hematoxylin & eosin and TUNEL staining showed 
that the apoptotic cells could be reduced after anti-HMGB1 mAb treatment. The onset and latency of 
Racine stage five were significantly prolonged in the anti-HMGB1 mAb group. These results suggested 
that anti-HMGB1 mAb prevented the BBB permeability, reduced HMGB1 translocation while inhibiting 
the expression of inflammation-related factors, protected against neural cell apoptosis and prolonged 
Racine stage 5 seizure onset and latency.
Epilepsy is a disabling neurological disorder affects around 60 million people of all ages worldwide1, 2. In about 
30% of affected individuals, epilepsy is refractory to pharmacological treatment and if not treated well could lead 
to brain damage or death3. The mechanism involved in the pathogenesis of epilepsy is not well understood4–6. 
Temporal lobe epilepsy (TLE) is the most common form of partial epilepsy, affecting at least 20% of all seizure 
patients7. Pilocarpine-induced epilepsy is a well-established animal model for status epilepticus (SE) and has also 
been reported as a good candidate for human TLE8.
Some models of epilepsy have revealed neuronal cell damage and loss in the CA1 and CA3 regions and dentate 
gyrus of the hippocampus9. A recent study on TLE also indicated atrophy, neuronal loss and gliosis in the DG, 
CA1, and CA3 regions, the entorhinal cortex and the amygdala10. Epilepsy is often associated with breakdown of 
the blood-brain barrier (BBB) altered peripheral immune response, and neuronal network reorganization11–15. 
Inflammatory processes in brain tissue have been described in human epilepsy of various etiologies and in exper-
imental models of seizures. Indeed, recent data suggest that inflammation may play an important role in the 
pathogenesis of epilepsy6.
HMGB1, a non-histone DNA-binding protein, has been suggested to play important roles in the regulation 
of gene expression, DNA repair, and maintenance of chromatin structure. HMGB1 shares 100% amino acid 
sequence identity between mice and rats, and a 99% homology between rodents and humans16, 17. Once the tis-
sues are damaged by any of several causes, HMGB1 might be released from necrotic cells passively, as well as 
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from living cells, including macrophages, neurons18, astrocytes19 and hepatocytes20. In ischemic21 or traumatic 
brain injury22, the HMGB1 released from the neuronal nucleus induces a contractile response in pericytes and 
vascular endothelial cells and disrupts the integrity of the BBB, leading to the augmentation of brain inflamma-
tory responses.
Thus, HMGB1 appears to be a mediator of the neurovascular unit, and excessive HMGB1 release may be asso-
ciated with brain injury and dysfunction23. Maroso et al.24 showed that kainate injection into the hippocampus 
induced ictogenesis through the release of HMGB1 and TLR-4 stimulation, at the same time increased expres-
sion of HMGB1 had been found in human and rat epileptic brain. Therefore, we hypothesized that HMGB1, as 
a pro-inflammatory cytokine-like molecule, might be involved in the development of epileptogenesis, especially 
through BBB disruption and induction of inflammatory processes. This study was designed to determine whether 
HMGB1 is involved in the pathogenesis of epilepsy or the ability of anti-HMGB1 mAb to protect BBB permea-
bility, neurons and inflammation.
Results
Effects of anti-HMGB1 mAb on BBB integrity under an acute epileptic state. As shown in Fig. 1a, 
pilocarpine-induced acute status epilepticus dramatically increased the leakage of Evans blue, especially into the 
thalamus and hypothalamus regions (Fig. 1b). However, after anti-HMGB1 mAb treatment the concentration of 
Evans blue dye decreased during pilocarpine-induced acute status epilepticus, while the control IgG group did 
not show any reduction in BBB leakage. The quantitative analysis revealed that the Evans blue levels were signif-
icantly increased in the PBS and control IgG groups compared to the sham and anti-HMGB1 treatment groups.
Injection of recombinant human HMGB1 after pilocarpine (300 mg/kg) enhanced the leakage of Evans blue 
dye in an HMGB1 dose-dependent manner (Fig. 1d). This result indicated that HMGB1 would promoted the BBB 
breakdown under an epileptic state. Quantification analysis indicated that the i.v. administration of exogenous 
recombinant human HMGB1 to mice enhanced the pilocarpine-induced BBB permeability in a dose-dependent 
manner.
Detection of HMGB1 dynamics after pilocarpine injection. HMGB1 translocation from the brain 
into peripheral blood is increasingly recognized as a crucial reason for the inflammation response during epilep-
togenesis. In this research, the amounts of HMGB1 in the brain and plasma were detected by Western blot and 
Figure 1. Effect of anti-HMGB1 mAb on BBB permeability in pilocarpine-induced acute status epilepticus. 
The permeability of brain capillary vessels was examined by intravenously injecting Evans blue (100 mg/kg, 
i.v.). Anti-HMGB1 mAb (1 mg/kg), control IgG, PBS was administered intravenously to mice which reached 
Racine stage 5 after onset of epilepsy (a). The distribution of Evans blue in brain were significantly shown in 
thalamus and hypothalamus region (b). The leakage of Evans blue into the brain parenchyma was quantified at 
4 h after anti-HMGB1, control IgG or PBS injection, and the results are expressed as the means ± SEM of 5 mice. 
**p < 0.01, &p < 0.05 and #p < 0.05 vs. Sham, PBS and Control IgG, respectively (c). The effects of intravenous 
administration of different concentrations of exogenous rhHMGB1 on BBB permeability after pilocarpine 
treatment are shown (d). The results were expressed as the means ± SEM of 7 mice. *p < 0.05 compared with 
Pilo + HMGB1 100 μg (e).
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ELISA. Acute status epilepticus led to a significant reduction of the amount of HMGB1 in the cerebrum due to 
the HMGB1 translocation (Fig. 2a). However, treatment with anti-HMGB1 mAb partially inhibited the HMGB1 
translocation and increased the amount of HMGB1 in mice in an acute status epilepticus compared with the PBS 
and control IgG groups. At the same time, the plasma concentrations of HMGB1 were significantly higher in the 
PBS and control IgG groups than in the sham and anti-HMGB1 mAb-treatment groups, indicating an increase in 
HMGB1 translocation into the peripheral circulation (Fig. 2c). Anti-HMGB1 mAb significantly suppressed the 
HMGB1 levels in plasma.
These results clearly demonstrated that anti-HMGB1 mAb treatment suppressed the acute status 
epilepticus-induced translocation of HMGB1 into the peripheral circulation.
Evaluation of HMGB1 translocation in the CA1 hippocampal and cerebral cortex regions by 
immunofluorescence staining. Under normal conditions in the present study, almost all CA1 neurons 
showed HMGB1-immunoreactivity in the nucleus (Fig. 3a). However, pilocarpine treatment caused translocation 
of HMGB1 from the nuclei, resulting in decrease in HMGB1 fluorescence intensity in the nuclei and increase in 
the number of released HMGB1 particles (yellow arrows) out of the nuclei (Fig. 3a,b,c). We graded the immuno-
fluorescence intensity in each nuclei into 9 levels and counted the cell numbers with the indicated fluorescence 
levels. Figure 3b summarized the results in CA1 hippocampal region. Apparently, the cell numbers with high 
HMGB1 immunofluorescence in nuclei decreased in pilocarpine-injected PBS and control IgG groups compared 
with those in sham group whereas the cell numbers with lower HMGB1 immunofluorescence in nuclei increased 
in pilocarpine-injected groups. Treatment with anti-HMGB1 mAb not only inhibited the distribution pattern 
of histogram to the left direction by pilocarpine but also the number of small granules outside nuclei (Fig. 3b,c). 
Similar results were found in the cerebral cortex neurons (Fig. 3d,e,f).
These results strongly suggested that HMGB1 translocation and release occurred in the CA1 and cerebral 
cortex regions under an acute epileptic state, and anti-HMGB1 mAb treatment could inhibit the HMGB1 trans-
location into the cytoplasm and extracellular space (Fig. 3).
Histochemical staining. In our previous study, we observed degenerated neurons in the hippocampus after 
brain injury22, and cytoplasm pyknosis and cell shrinking were the two main morphological changes. In this 
experiment, we found a similar type of cells in the CA1 hippocampal region after acute status epilepticus, and 
some of these pyknotic cells showed the condensed hematoxylin staining. Acute epileptic state increased the 
number of pyknotic and shrunk cells, but anti-HMGB1 mAb treatment significantly reduced the number of 
pyknotic cells. The pyknotic cells are indicated by the black arrows in Fig. 4a. The number of pyknotic cells was 
significantly decreased after anti-HMGB1 mAb treatment (Fig. 4b).
Apoptotic cells are shown as a dark-brown color by TUNEL staining, and these cells could be detected in 
both the PBS control and control IgG groups. However, there were fewer apoptotic cells in the CA1 hippocampal 
Figure 2. Dynamic changes of HMGB1 content in brain and plasma in pilocarpine-induced acute status 
epilepticus. The content of HMGB1 in the cerebrum was measured by Western blotting 4 h after anti-HMGB1, 
control IgG or PBS injection. The β-actin was used as a reference protein. Representative results are shown for 
each group of 2–3 mice (a). The brain levels of HMGB1 are shown as the means ± SEM of 9 mice. *p < 0.05, 
**P < 0.01 compared with the sham control, &&p < 0.01 compared with the PBS control, #p < 0.05 compared 
with the control IgG group (b). Plasma levels of HMGB1 were determined by ELISA at 4 h after onset of seizure 
. The results are shown as the means ± SEM of 9 mice. *p < 0.05 compared with the sham control, &p < 0.05 
compared with the PBS control, #p < 0.05 compared with the control IgG group (c).
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region after anti-HMGB1 mAb treatment. In the sham group, no prominent apoptotic cell morphology was 
observed (Fig. 4c), while anti-HMGB1 mAb dramatically reduced the number of apoptotic cells after acute status 
epilepticus. From these results, it could be concluded that anti-HMGB1 mAb conferred protective effects on CA1 
hippocampal neurons under an acute epileptic state (Fig. 4).
Morphological changes of astrocytes and microglial cells in the CA1 and dentate gyrus hip-
pocampal regions by immunofluorescence staining. Epilepsy is usually accompanied by the acti-
vation of astrocytes and microglial cells, and these activations promote inflammatory cytokine release and 
accelerate the inflammation response. In response to seizure, a proportion of reactive astrocytes and microglia 
cells proliferate, and this process could increase the number of astrocytes and microglia cells at the epileptic 
lesion site. The typical reactive phenotype of astrocytes characterized by the distinct thickening and hypertrophy 
could be accompanied by up-regulated GFAP expression. Activated microglia cells show fewer ramified process 
with the soma enlargement or “bushy” phenotypes. Hence, we counted the total number and activated astrocytes 
and microglial cells number under the acute epileptic state in this model. Immunohistochemical study revealed 
that the numbers of activated astrocytes and microglia had increased in the CA1 region of epileptic mice after 
treatment with PBS or in the Control IgG mice. Anti-HMGB1 mAb treatment significantly reduced the num-
ber of astrocytes and microglial cells while simultaneously maintaining or recovering their original cell shape 
(Fig. 5a,b,e,f). A similar trend was seen in the dentate gyrus region (Fig. 5c,d,g,h).
The neutralization of HMGB1 by anti-HMGB1 mAb significantly suppressed the acute status 
epilepticus-caused astrocytes and microglia cells activation.
Evaluation of IL-1β expression in the CA3 region and thalamus under an acute status epilepti-
cus. Since IL-1β is thought to be a pro-inflammatory cytokine that participates in the regulation of immune 
and inflammatory responses. We counted the number of highly IL-1β immunoreactive cells and measured the 
fluorescence intensity derived from acute status epilepticus. These specific cell were shown in the left insets from 
the PBS control, control IgG group and in the middle inset from anti-HMGB1 mAb group (Fig. 6a,d). We found 
that IL-1β was expressed at very low levels in the nuclei of CA3 pyramidal cells and thalamic cells in intact mice. 
The expression of IL-1β in intact mice was restricted to the perinuclear regions, but IL-1β in the PBS and control 
Figure 3. The translocation and release of HMGB1 in neurons in pilocarpine-induced acute status epilepticus. 
Anti-HMGB1 mAb, control IgG or PBS was administered to stage 5 epileptic mice, and the brains were fixed 
4 h later. The CA1 hippocampal region (a) and cerebral cortex (b) were double-stained with anti-HMGB1 
and anti-MAP2 antibodies, followed by Alexa Fluor 555-labeled and Alexa Fluor 488-labeled secondary 
antibodies, respectively. Scale bars equal 30 μm (a) and 50 μm (d), respectively. Arrowheads (white) indicate 
the neurons with marked decrease in HMGB1 fluorescence intensity in nuclei. Arrows (yellow) indicate the 
HMGB1-positive small particles released from nuclei (a). The fluorescent intensity of HMGB1 in nuclei was 
graded into 9 levels and the cell numbers with the indicated fluorescent levels were counted (b,e). The total 
number of HMGB1-positive small particles were also counted in each group (c,f). The results are shown as 
the means ± SEM of 8 mice. **p < 0.01 compared with the corresponding sham control. &p < 0.05, &&p < 0.01 
compared with PBS control. #p < 0.05, ##p < 0.01 compared with the control IgG group (b,c,e,f).
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IgG mice was more diffusely distributed inside the cells, while at the same time the intensity of staining in the PBS 
and control IgG mice was much higher than in the sham group (Fig. 6a,d).
Anti-HMGB1 treatment also remarkably inhibited the number and the fluorescence intensity of highly IL-1β- 
immunoreactive cells in both the CA3 and thalamus (Fig. 6b,c,e,f).
Determination of inflammation-related molecules in the hippocampus and cerebral cortex 
under an acute epileptic state. Inflammation-related molecules were produced and released from dam-
aged cells during the period of epilepsy, followed by the exacerbation of BBB disruption and inflammation. The 
expressions of hippocampal MCP-1, CXCL-1, TNF-α, HIF-1α, and TLR-4 were significantly upregulated in the 
PBS and Control IgG-treatment groups, whereas anti-HMGB1 antibody treatment suppressed the hippocampal 
expression of these inflammation-related factors (Fig. 7a). A similar trend was observed in the cerebral cortex 
region (Fig. 7b).
Behavior and latency test. Pretreatment of anti-HMGB1 mAb 4 h before pilocarpine treatment reduced 
the Racine stage 5 frequencies, and increased both the latency to stage 5 and the time to death (Fig. 8a). Moreover, 
anti-HMGB1 mAb treatment immediately after pilocarpine injection increased the latency to onset and to the 
stage 5, while at the same time lowering the stage 5 frequency (Fig. 8b).
Discussion
The cholinergic agonist pilocarpine has been widely used experimentally to mimic SE in rodents. 
Pilocarpine-induced epilepsy is triggered primarily by the activation of M1 muscarinic receptors in the central 
nervous system (CNS), and the seizures are maintained by N-Methyl-D-aspartate (NMDA) receptor activation25. 
Systemic administration of pilocarpine in rodents reproduces the principle features of human TLE26, i.e., limbic 
seizures, secondary generalized seizures and SE that lasts for several hours26, 27.
BBB disruption and inflammatory responses have been strongly suggested to be involved in the epileptogenic 
process for decades. In fact, Evans blue dye leakage after pilocarpine injection in mice was previously reported28 
and was confirmed in the present study. Although there are many candidate molecules for induction of the 
increase in BBB permeability, the fact that a specific antibody against HMGB1 significantly inhibited the BBB 
Figure 4. Histological analysis of neuron degeneration and apoptosis in the CA1 hippocampal region in 
acute status epilepticus mice. The brains were fixed with formalin at 4 h after anti-HMGB1, control IgG or PBS 
administration, and paraffin-embedded sections were stained with hematoxylin-eosin. Arrows indicate typical 
pyknotic cells. Scale bars equal 50 μm. *p < 0.05, **p < 0.01 compared with the sham. &&P < 0.01 compared 
with the PBS control. #p < 0.05 compared with the control IgG group (a). The number of pyknotic cells was 
counted in each mouse and the results are shown as the means ± SEM of 8 mice (b). Apoptotic cells were 
detected by TUNEL staining. The arrows indicate the apoptotic cells (c). The number of apoptotic cells in the 
CA1 region was counted in each mouse and the results are shown as the means ± SEM of 8 mice. **p < 0.01 
compared with the sham control. &&p < 0.01 compared with the PBS control. ##p < 0.01 compared with the 
control IgG group (d).
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permeability clearly demonstrated that HMGB1 is one such molecule and plays an important role in the increase 
in BBB permeability in the acute phase of epilepsy. Moreover, we found that the BBB disruption was exacerbated 
after the administration of exogenous HMGB1, implying the possible influence of systemic inflammation on vas-
cular damage in the brain, which has also been reported in experimental stroke29 and brain trauma22 in addition 
to status epilepticus30.
Taken together, the translocation of HMGB1 in neurons, decreased HMGB1 levels in the brain and increased 
HMGB1 level in plasma in mice with pilocarpine-induced epilepsy support the notion that HMGB1 was trans-
located and released from neuronal nuclei into the surrounding areas, including the blood stream. Choy et al.31 
and Patterson et al.32 also revealed that HMGB1 could be translocated from nuclei to the cytoplasm in neuronal 
cells at 1 and 3 h after experimental febrile status epilepticus. The mobilization pattern and dynamics of HMGB1 
in mice with pilocarpine-induced epilepsy were quite similar to those observed in ischemia18, 21 trauma22 and 
neurotoxin19 induced injuries. Moreover, the inhibition of HMGB1 mobilization by anti-HMGB1 was common 
to different types of brain injuries, suggesting the existence of HMGB1-induced mechanisms of HMGB1 release 
in all brain injuries examined. Recent studies have suggested that a chemical modification of HMGB1 is respon-
sible for the initiation of translocation33, 34. Therefore, there might be a common signaling mechanism leading 
to chemical modification among the different insults. In a previous study21, our group demonstrated the direct 
effects of HMGB1 on vascular endothelial cells and pericytes leading to contractile responses of these cells and 
the BBB breakdown. Based on these findings, it was speculated that both HMGB1 release into the CNS and 
HMGB1 release into the peripheral blood stream after pilocarpine injection contributed to the induction of BBB 
breakdown.
Li et al. reported that microglial activation in the hippocampus was suppressed after an intraventricular injec-
tion of anti-HMGB1 antibody in status epilepsy induced by intraventricular KA injection35. The activation of 
astrocytes and microglia in pilocarpine-induced acute status epilepticus was also confirmed by the increase in 
the number of cells and the activation-specific cell shape not only in the hippocampal but also the cerebral cortex 
regions. This activation of cells was significantly inhibited by the systemic administration of anti-HMGB1 mAb. 
Thus, the treatment of anti-HMGB1 mAb not only decreased BBB breakdown but also suppressed the activity of 
intrinsic inflammatory cells in the brain. Consistent with these findings, the determination of the expression of 
a representative pro-inflammatory cytokine, IL-1β, by immunohistochemistry clearly revealed the upregulation 
Figure 5. Morphological changes of astrocytes and microglia cells in the hippocampus and dentate gyrus of 
mice under acute status epilepticus. Anti-HMGB1 mAb, control IgG or PBS was immediately administered to 
mice reached Racine stage 5 and sacrificed 4 h later. The brain sections were stained with anti-GFAP (green) 
and DAPI (blue). The total number and activated astrocytes in the CA1 (a) and dentate gyrus (c) were counted 
in each group and the results are shown as the means ± SEM of 8 mice. Black bar showed the total number of 
astrocytes and the gray bar showed the number of activated astrocytes. **p < 0.01 compared with the sham 
control. &p < 0.05, &&p < 0.01 compared with the PBS control. #p < 0.05, ##p < 0.01 compared with the control 
IgG group (b). **p < 0.01 compared with the sham control. &&p < 0.01 compared with the PBS control. 
#p < 0.05, ##p < 0.01 compared with the control IgG group (d). The brain sections were stained with anti-Iba1 
(green) and DAPI (blue). The total number and active/amoeboid Iba1-positive cells were counted in the 
hippocampus (e) and dentate gyrus (g) in each group and the results are shown as the means ± SEM of 8 mice. 
*p < 0.05, **p < 0.01 compared with the sham control. &p < 0.05 compared with the PBS control. #p < 0.05 
compared with the control IgG group (f). **p < 0.01, **p < 0.05 compared with the sham control. &p < 0.05, 
&&p < 0.01 compared with the PBS control. #p < 0.05 compared with the control IgG group (h). Scale bars equal 
50 μm.
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of IL-1β in neurons in the hippocampus and thalamus in pilocarpine-induced acute status epilepticus in mice. 
The up-regulation of IL-1β expression was once again significantly inhibited by the anti-HMGB1 administra-
tion. Furthermore, quantitative RT-PCR revealed that the up-regulated expressions of MCP-1, TNF-α, IL-6 and 
CXCL-1 were all suppressed by anti-HMGB1 mAb treatment. Since these cytokines are suggested to be involved 
in epileptogenesis through the amplification of inflammation36 and neural network remodeling in kindling37 as 
well as kainate-induced model38, it is likely that anti-HMGB1 treatment can inhibit the downstream processes 
induced by these cytokines. Among the up-regulated cytokines, IL-1β has been reported to form a complex with 
HMGB1, and the resultant complex increased the affinity of IL-1β to IL-1β receptors39, 40. Therefore, it is worth 
noting that the inhibitory effects of anti-HMGB1 on IL-1β expression are particularly important with regard to 
the suppression of enhanced and synergistic inflammation by the combination of HMGB1 and IL-1β. Moreover, 
the effects of HMGB1 and IL-1β appear to be very similar, as both are blocked by ifenprodil, a selective antagonist 
of NR2B containing NMDA receptors41, suggesting the involvement of glutamate downstream of HMGB1 and 
IL-1β action. Inhibition of inflammatory factors is becoming a novel component in the recently proposed etiol-
ogies for epilepsy36. However, the simultaneous suppression of several inflammatory cytokines by a single drug 
would be difficult. Nonetheless, anti-HMGB1 mAb would seem to be a candidate for such a drug therapy, due to 
its ability to inhibit the expression of a diverse range of inflammation-related molecules.
Maroso et al. demonstrated that microinjection of exogenous HMGB1 into the hippocampus in mice 
dose-dependently enhanced the seizures induced by kainate through the stimulation of TLR-4. They also sug-
gested the involvement of RAGE, another receptor for HMGB142 in kainate-induced seizures in mice43. Since 
we observed the release of HMGB1 from hippocampal pyramidal cells in the present study, and pilocarpine 
was reported to induce glutamate release44, it is quite likely that the released HMGB1 produced the synergistic 
effects with excitatory glutamate leading to induction of seizures24 as well as neuronal apoptosis45. The inhibitory 
effects of anti-HMGB1 on TLR-4 expression further support the beneficial effects of anti-HMGB1 treatment. In 
fact, anti-HMGB1 treatment significantly inhibited the apoptosis of pyramidal cells. Thus, it was speculated that 
anti-HMGB1 treatment could contribute not only to the suppression of BBB disruption and brain inflammation 
but also to the prevention of neuronal cell death.
Epilepsy has a complex pathophysiology. Recurrent seizures have been shown to result in the progressive 
development of susceptibility to sub-convulsive stimuli46. To induce such a state, reorganization of the neuronal 
network and phenotypic changes in glial cells may take place, in association with BBB breakdown, disorder of the 
Figure 6. Expression of IL-1β in the CA3 hippocampal region and the thalamus of mice under acute status 
epilepticus. Anti-HMGB1 mAb, control IgG or PBS was administered intravenously when mice reach Racine 
stage 5 by pilocarpine administration and sacrificed 4 h later. The brains were fixed by formalin and paraffin-
embedded sections were stained with anti-IL-1β antibody. The hippocampal CA3 (a) and thalamus region (d) 
were under observation. The number of highly IL-1β immunoreactive cells (b) and the fluorescence intensity 
(c) were analyzed in hippocampus CA3. **p < 0.01 compared with the sham group. &p < 0.05 compared 
with the PBS group. ##p < 0.01, #p < 0.05 compared with the control IgG group. The results are shown as the 
means ± SEM of 8 mice. The number of highly IL-1β immunoreactive cells (e) and the fluorescence intensity 
(f) were analyzed in thalamus. The results are shown as the means ± SEM of 8 mice. **p < 0.01, *p < 0.05 
compared with sham group. &&p < 0.01, &p < 0.05 compared with the PBS group. ##p < 0.01, #p < 0.05 compared 
with the control IgG group (d). Scale bars equal 50 μm.
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neurovascular unit, activation of microglia and astrocytes, and up-regulation of inflammation-related molecules, 
including cytokines. Our findings that anti-HMGB1 suppressed the important underlying processes of epilepsy, 
such as BBB breakdown, inflammation and neuronal apoptosis, strongly suggested that the mobilized HMGB1 
from neuronal nuclei during seizure may in turn facilitate a diverse range of events in obtaining epileptogen-
esis. Overall, the treatment with anti-HMGB1 mAb in the present study prolonged the latency of stage 5 and 
reduced the frequencies of seizure stage 5 in pilocarpine-induced acute epilepsy. These anti-epileptic effects of 
anti-HMGB1 mAb are probably due to the inhibition of BBB disruption, inflammatory responses and neuronal 
cell death. In other words, it is likely that HMGB1 mediates the recurrence and progression of epilepsy through 
the damage of BBB and induction of inflammation. The A box domain of HMGB1, an alternative to inhibit 
HMGB1 action as an antagonist for RAGE, has been administered intracerebroventricularly in many cases. The 
route of administration and half-life of the A box domain would limit its clinical use. Also, the efficacy of some 
small molecules which have been suggested to inhibit HMGB1 were limited. In contrast, intravenous injection of 
antibody is simple and convenient and usually has a longer half-life than HMGB1 A box domain and the small 
molecules antagonist24.
Figure 7. Determination of the expression of inflammation-related molecules by quantitative real-time PCR 
in the hippocampus (a) and cerebral cortex (b) in mice with pilocarpine-induced acute status epilepticus. 
Anti-HMGB1, control IgG or PBS was administered intravenously when mice reached Racine stage 5 after 
pilocarpine. Brain samples were collected 24 h after antibody administration. The results were normalized to the 
expression of GAPDH and are expressed as the means ± SEM of 11 mice. *p < 0.05, **p < 0.01 compared with 
the sham group. &p < 0.05, &&P < 0.01 compared with the PBS control. #p < 0.05, ##p < 0.01 compared with the 
control IgG group (a,b).
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It is well-known that traumatic injury to the brain frequently causes post-traumatic epilepsy. Acute injury to 
the cerebral cortex by fluid percussion in rats produced a marked brain swelling that was strongly inhibited by 
administration of anti-HMGB1 mAb after the onset22. The analysis of a mechanism for protecting the BBB in this 
animal model clearly showed that anti-HMGB1 strongly inhibited the translocation and release of HMGB1 from 
neuronal nuclei and the subsequent cascade of inflammatory events very efficiently22. Thus, the treatment with 
anti-HMGB1 not only protected against acute brain damage but also suppressed the epileptogenic responses in 
the brain. At present, we do not have any knowledge about the spontaneous and continuous release of HMGB1 
within a possible epileptic focus in the subacute or chronic phase of brain injury. Based on the present results, 
this type of HMGB1 release should accelerate the epileptogenesis. Further studies will be needed to examine this 
possibility.
In conclusion, we demonstrated for the first time that intravenous treatment with neutralizing anti-HMGB1 
mAb conferred protective effects on neuronal apoptosis, in association with an inhibition of HMGB1 release, 
protection of the BBB and inhibition of inflammation in a very-acute-phase of status epilepticus induced by 
pilocarpine. These effects of anti-HMGB1 mAb as a whole appear to lead to the prolongation of seizure latency 
and seizure frequencies in pilocarpine-induced acute status epilepticus. Thus, anti-HMGB1 therapy may provide 
a novel strategy for controlling the epileptogenesis.
Materials and Methods
Animals. Female C57BL/6 N mice (Charles River Laboratory, Japan, Yokohama, Japan) weighing 18 to 23 g 
were used. Mice were housed in isolator cages with free access to food and water in a room maintained at a 
constant temperature of 23 °C on a 12-h light-dark cycle. The experimental protocols are described in Fig. 1. All 
animal experiments were approved (OKU-2014-96) by the Institutional Animal Care and Use Committee of 
Okayama University, and performed according to the guidelines of Okayama University on animal experiments.
Model of pilocarpine-induced epileptic state. Mice were pre-treated with methyl-scopolamine bro-
mide (Sigma-Aldrich Co., St. Louis, MO, USA) (1 mg/kg, i.p.) followed by pilocarpine (Wako, Japan) (350 mg/kg 
or 300 mg/kg, i.p.) 30 min later. Anti-HMGB1 mAb (#10–22, immunoglobulin G (IgG2a) subclass, 1 mg/kg, i.v.), 
class-matched control IgG mAb (anti-keyhole limpet hemocyanin, 1 mg/kg, i.v.), or PBS was administered intra-
venously 1 min after first stage 5 seizure. The average time interval between pilocarpine injection and first stage 
5 was 24 ± 1.9 min. The Racine stage47 was used as a criterion. Mice under Racine stage 5 seizure were excluded 
from this experiment. Mice were assigned randomly to each group. Sound and light stimulations were prohibited 
during the experiment. The sham group received a comparable intravenous injection of 10 mM PBS. A heating 
pad was used to maintain the body temperature of mice at 37 ± 0.5 °C.
A schematic was used for stating the experimental design, drug doses and subsequent process (Fig. 9).
Figure 8. The pre-treatment and post-treatment of anti-HMGB1 mAb on acute seizure behavior. Pre-
treatment: Anti-HMGB1 mAb, control IgG or PBS was administered intravenously 4 h before pilocarpine 
(350 mg/kg, i.v.) injection. All data were collected in 60 min after pilocarpine treatment. The frequency of 
seizure stage 5, latency to stage 5 and the time to death were determined on each mouse. The results are 
shown as the means ± SEM of 9 mice. &p < 0.05, compared with the PBS control. #p < 0.05, compared with the 
control IgG group (a). Post-treatment: anti-HMGB1 mAb, control IgG or PBS were immediately injected after 
pilocarpine injection, and behavior test were observed under 60 min observation. The latency to onset and stage 
5 and the frequency of stage 5 were determined on each mouse. The results are shown as the means ± SEM of 11 
mice. &p < 0.05, compared with the PBS control. #p < 0.05, compared with the control IgG group (b).
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Measurement of BBB permeability. BBB permeability (Fig. 9, protocol #1a) was assessed by measuring 
the extravasation of Evans blue into the brain. Mice were divided into four groups: sham, PBS control group, con-
trol IgG group, and anti-HMGB1 mAb group (n = 5 in each group). Pilocarpine was administered to trigger the 
acute epileptic state, and then the mice that reached Racine stage 5 were selected and injected with PBS, control 
IgG or anti-HMGB1 mAb. Two hours later, Evans blue (100 mg/kg) was injected via the tail vein under an awake 
state28, then allowed to circulate for 2 h prior to sacrifice. The measurement of BBB permeability was performed 
by the Evans blue absorbance at 620 nm. See details in the Supplemental Methods.
To determine whether increases in plasma HMGB1 accelerate the BBB breakdown in pilocarpine-induced 
epilepsy, the recombinant human HMGB1 was immediately given via the tail vein after pilocarpine injection 
(Fig. 9, protocol #2). Mice were divided into six groups: sham group, sham with 100 μg rhHMGB1 group, pilocar-
pine (300 mg/kg, i.v.) plus PBS group, and pilocarpine plus 10, 50, or 100 μg rhHMGB1-treatment groups (n = 7 
in each group). Mice in the sham and sham with 100 μg rhHMGB1 group received PBS instead of pilocarpine. The 
measurement of BBB permeability was performed as described above18, 22, 28.
Measurement of HMGB1 concentrations in the cerebrum and plasma during the acute phase of 
status epilepticus. For determination of the HMGB1 concentration in plasma (Fig. 9, protocol #1b), samples 
were collected through the inferior vena cava under deep anesthesia with sodium pentobarbital (50 mg/kg, i.p.). 
After being centrifuged at 1500 g for 10 min, the sample supernatants were supplemented with protease inhibitor 
(Sigma) (50 μl/g) and stored at −20 °C before use. Mice were divided into four groups (n = 9 in each group). 
Plasma levels of HMGB1 were determined by enzyme-linked immunosorbent assay (Shino-Test Co., Sagamihara, 
Japan) as described previously21.
The HMGB1 content in the cerebrum (Fig. 9, protocol #1b) was determined by Western blot according to the 
methods described previously21. Brain samples were collected 4 h after injection of anti-HMGB1 mAb, control 
IgG or PBS under an acute status epilepticus (n = 9 mice in each group). See details in the Supplemental Methods.
Histochemical staining and TUNEL assay. Samples were collected 4 h after anti-HMGB1, control IgG 
or PBS injection under acute seizure condition. The brains of the epileptic mice (Fig. 9, protocol #1c, d) were 
perfused with 0.9% Nacl from the left ventricle, then fixed with 10% formalin and post-fixed overnight in 10% 
formalin at 4 °C. The samples were then embedded in paraffin and cut at a thickness of 5 µm. Brain sections were 
stained with hematoxylin–eosin18. Changes in the morphology of cells in the CA1 hippocampal region were 
observed under a BZ-X700 All-In-One fluorescence microscope (Keyence, Oosaka, Japan).
Apoptotic cells were measured by the in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin 
nick end-labeling (TUNEL) method (Fig. 9, protocol #1) using an in situ Apoptosis Detection Kit (Takara, Shiga, 
Japan) as previously described48. Morphological changes of nuclei were observed under a BZ-X700 All-In-On 
fluorescence microscope (Keyence, Oosaka, Japan).
Immunofluorescence staining. For immunofluorescence staining (Fig. 9, protocol #1c), the mice were 
divided into 4 groups with 8 mice in each group. Mice were treated as described in protocol #1 histochemical 
staining section above. Paraffin-embedded brain sections (5 μm) were stained using a mouse anti-HMGB1 mAb 
(R&D Systems Inc.), rabbit anti-MAP2 pAb (Santa Cruz Biotechnology Inc.) for HMGB1 detection. For astro-
cytes and microglia cells staining rabbit anti-GFAP pAb (Abcam, Cambridge, UK), rabbit anti-Iba-1 Ab (Wako, 
Osaka, Japan) were used. Rabbit polyclonal anti-IL-1β antibody (Abcam, Cambridge, UK) were used for IL-1β 
detection as the primary antibody. See details in the Supplemental Methods.
Figure 9. A schematic of the experimental design, drug doses and subsequent processes. Protocol #1: Racine 
stage 5 seizures were induced by pilocarpine which were then treated with PBS, control IgG or anti-HMGB1 
mAb for 4 h, then sacrificed, and examined for the BBB permeability, the translocation of HMGB1 (a,b,c), 
and the apoptosis cells under acute status epilepticus (d). Protocol #2: Mice were administered 10, 50, or 
100 μg of human recombinant HMGB1 for 4 h under status epilepticus condition, then BBB permeability was 
determinated by Evans blue again. Protocol #3: Epileptic mice were treated with PBS or control IgG or anti-
HMGB1 mAb for 24 h, then subjected to RT-PCR analyses. Protocol #4: Mice were injected with pilocarpine 
and either PBS, control IgG or anti-HMGB1 mAb, then immediately subjected to a seizure latency test, followed 
by a behavior test under 1 h post-treatment. Protocol #5: Mice were pretreated with PBS, control IgG or anti-
HMGB1 mAb for 4 h before pilocarpine induction followed by behavior and latency test in 1 hour.
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Cell morphology and cell counting quantification. The H&E staining was used for identifying the 
pyknotic cells. The apoptotic cells were defined as those with nuclear staining with a dark-brown color using 
TUNEL method as described above. Under normal condition, neurons showed HMGB1- immunoreactivities in 
the nuclei. Reactive astrocytes usually shown as cell swelling with fine spongiform process with a greater number 
of main process extending from the soma and the GFAP immunoreactivity exhibited a distinct increase49. We 
set two criteria to identify activated astrocytes: 1) the thickness of main process were over 2.5 μm; 2) the length 
of processes from soma was more than 15 μm. Astrocytes met both criteria were identified as activated astrocyte 
and counted. Under resting conditions, microglia in the CNS were ramified. The resting microglial cells were 
characterized by a small cell soma and several branching thin processes that extend in all directions. However, 
when brain insult causes a transformation from ramified into activated microglia even an amoeboid form, these 
processes retracted microglia cell processes and become fewer and much thicker. At the same time, the size of the 
cell bodies will increase. Then, the criteria for activated microglia were 1) the thickness of process was over 3 μm; 
2) the cell soma was oval shape and the longest diameter was longer than 12 μm; 3) the visible processes were 
shorter than 5 μm from the soma. Microglia cells met these three criteria were identified as activated microglia 
and counted. The highly IL-1β-immunoreactive cells were identified as those having more than four times higher 
intensity of fluorescence companied with sham average control cells in the same area.
The number of pyknotic and apoptotic cells were counted on 3 serial sections per animal and four randomly 
selected squares (50 × 50 μm2) in each section and counted the total number from these squares in the CA1 hip-
pocampal region. The same procedure was performed when determining the HMGB1 fluorescence intensity in 
nuclei on the brain sections from each mice and counting the number of HMGB1-positive small particles in CA1 
(30 × 30 μm2) and in cerebral cortex (50 × 50 μm2). The number of specific cells in these squares were counted 
by blind investigators who were unaware of the groups and statistically analyzed. The GFAP- and Iba-1-stained 
sections were used for counting the total number and the activated number of astrocytes and microglia cells, 
respectively in the square area of 100 × 100 μm2. The number of IL-1β specific cells were counted on 50 × 50 μm2 
squares in CA1 and thalamus by blind investigators. The fluorescence intensity of HMGB1 and IL-1β were meas-
ured by using Image J. All the procedures abided by the preclinical research standard50.
Real-time polymerase chain reaction. For analyzing the expression of inflammation-related molecules, 
samples were taken from the hippocampus and cerebral cortex 24 h after the treatment with anti-HMGB1 mAb, 
control IgG mAb or PBS under an epileptic state (n = 11 mice in each group) (Fig. 9, protocol #3). Total RNA was 
extracted from the mouse hippocampus and cerebral cortex by using an RNeasy mini kit (QIAGEN) according to 
the manufacturer’s protocol. The RNA was then reverse-transcribed to cDNA by a reverse transcriptase kit-RNA 
PCRT M Kit (AMV) Ver 3.0 (Takara, Shiga, Japan). The real-time polymerase chain reaction (RT-PCR) analy-
sis was performed as described previously18 using SYBR Premix EX Taq (Takara) in a Light Cycler instrument 
(Roche, Indianapolis, IN) according to the manufacturer’s instructions. The sense and antisense primer sequences 
were described in Supplementary Table S1.
The expression of GAPDH was used to normalize cDNA levels. PCR products were analyzed using a melting 
curve to ascertain the specificity of amplification.
Behavior and latency test. This experiment, we divided this part into two sections, firstly, mice were 
treated with PBS, control IgG (1 mg/kg) or anti-HMGB1 mAb (1 mg/kg) immediately after pilocarpine injection 
(n = 11 mice in each group) (Fig. 9, protocols #4). The time to the onset, first latency to stage 5 and the frequency 
of stage 5 were all recorded in an observation period of 60 min (Fig. 9, protocol #4).
Secondly, mice were pretreated with anti-HMGB1 mAb (1 mg/kg), control IgG (1 mg/kg) or PBS 4 h before 
pilocarpine (350 mg/kg) (n = 9 mice in each group) injection (Fig. 9, protocols #5). After the injection of pilocar-
pine, the time to the onset, first latency to stage 5, and the time to death were all recorded in an observation period 
of 60 min (Fig. 9, protocol #5). All the data were counted by an examiner who was blinded to the experimental 
protocol. Mice under Racine stage 5 were excluded from this experiment.
Statistical Analysis. Statistical significances were performed using one-way analysis of variance (ANOVA) 
followed by LSD (a = 0.05) or Dunnett test by IBM SPSS Statistics 19.0. Results were expressed as mean ± SEM. A 
probability value of <0.05 was considered to be significant.
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